Waters Shareholders Approve Share Issuance for BD Biosciences & Diagnostic Solutions Merger

summarizeSummary

Waters Corporation shareholders have approved the share issuance for the merger with BD's Biosciences & Diagnostic Solutions business, clearing a major hurdle for the transaction expected to close on February 9, 2026.

check_boxKey Events

• Shareholders Approve Merger-Related Share Issuance

  Waters Corporation shareholders overwhelmingly approved the issuance of common stock for the proposed Reverse Morris Trust transaction with BD's Biosciences & Diagnostic Solutions business, with approximately 99% of votes cast in favor.

• Key Merger Condition Met

  This shareholder approval fulfills a significant condition for the merger, which involves the spin-off of BD's business and its subsequent merger into a Waters subsidiary.

• Transaction Expected to Close February 9, 2026

  The transaction is now anticipated to close on February 9, 2026, subject to the satisfaction or waiver of remaining customary closing conditions.

• Q4 Earnings Call Rescheduled

  Waters has rescheduled its Q4 2025 financial results conference call to February 9, 2026, to coincide with the expected closing of the transaction.

auto_awesomeAnalysis

Waters Corporation's shareholders have overwhelmingly approved the issuance of shares necessary for the Reverse Morris Trust transaction with BD's Biosciences & Diagnostic Solutions business. This approval, with approximately 99% of votes in favor, removes a significant condition for the merger, following previous disclosures regarding the strategic rationale and financing. The transaction is now expected to close on February 9, 2026, marking a critical step towards combining the businesses and realizing the anticipated strategic and financial benefits. Investors should monitor the final closing of the transaction as scheduled.